AstraZeneca PLC
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| AZN.ST | LLY.NE | 4503.T | MRK | PFE | NVS | |
|---|---|---|---|---|---|---|
| Market cap | 2.88T | 1.74T | 4.79T | 370.96B | 175.50B | 311.59B |
| P/E (TTM) | 27.9 | 65.7 | 13.2 | 151.9 | 44.0 | 31.5 |
| Forward P/E | — | — | 35.3 | 16.7 | 10.6 | 16.6 |
| Price/book | 55.6 | 1.4 | 2.6 | 8.9 | 2.1 | 8.4 |
| Dividend yield | 1.64% | 0.58% | 3.11% | 2.26% | 5.59% | 2.87% |
| 1-year change | +14.73% | +35.37% | +47.30% | +75.29% | +23.90% | +30.35% |
| Today | +0.62% | +0.78% | +6.88% | +3.93% | +2.63% | +3.59% |
The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 20 min.
Latest news
All AZN.ST news ›AstraZeneca appoints Naveen Krishna Yamarthi as Managing Director, AstraZeneca India Private Limited (AZIPL) and Head of Global Innovation & Technology Centre, Chennai
Chennai, 04 November 2026: AstraZeneca announced the appointment of Naveen Krishna Yamarthi as Managing Director AZIPL and Head of its Global Innovation & Technology Centre (GITC), Chennai, effective 30 October 2026. In this role, Naveen…
OncoC4 Appoints Former AstraZeneca Executive Dan Janiak As Chief Business Officer
OncoC4, a clinical-stage biotechnology company developing cancer and immunology treatments, has appointed Dan Janiak, Ph.D., as Chief Business Officer. Janiak brings more than 15 years of experience in biotechnology financing, corporate…
AstraZeneca India appoints new MD and Chennai centre head
AstraZeneca India appoints Naveen Krishna Yamarthi as MD and GITC Chennai head to drive Bold Ambition 2030 and innovative tech-led growth. AstraZeneca on Tuesday announced the appointment of Naveen Krishna Yamarthi as Managing Director of…
AstraZeneca Gets Delhi HC Relief in Rs 151 Crore NPPA Overcharging Case
Susmita Roy, B pharm, M pharm Pharmacology, graduated from Gurunanak Institute of Pharmaceutical Science and Technology with a bachelor's degree in Pharmacy. She is currently working as an assistant professor at Haldia Institute of…
AstraZeneca targets $1.5B in savings; Ayrmid bids for Karyopharm; Sanofi pays $125M to Novavax
AstraZeneca is cutting costs and early cancer programs, while Ayrmid is pursuing another struggling U.S. drugmaker. This week’s six updates also include a Huntington’s gene therapy review, mixed MS data and new plans for vaccines and…
Boehringer Ingelheim and SBP Group enter partnership to advance next-generation cancer therapies
Cancer remains one of the world’s greatest health challenges, with approximately 20.6 million new cases and close to 10 million deaths annually. ADCs are designed to deliver potent therapeutic agents more selectively to cancer cells, while…
Nordic stocks in North America - AstraZeneca fell 1.0 percent
Stockholm New York New York Diff... Nordic stocks in North America - AstraZeneca fell 1.0 percent Published on 11/04/2026 at 12:52 am EST Stocks mentioned in the article Latest news about Nokia Oyj Income Statement and Estimates The more…
Gastric Cancer Market to Expand Rapidly by 2035 Amid Increasing Investments and Innovation | AstraZeneca, Daiichi Sankyo, Bristol-Myers Squibb, Amgen, Jazz Pharma, BeiGene, Zymeworks, ALX Oncology
Gastric Cancer Market to Expand Rapidly by 2035 Amid Increasing openPR.com Gastric Cancer Market to Expand Rapidly by 2035 Amid Increasing Investments and Innovation | AstraZeneca, Daiichi Sankyo, Bristol-Myers Squibb, Amgen, Jazz Pharma,…
Cutaneous Lupus Erythematosus Pipeline Analysis 2026: Phase III and Phase II Assets, MOA Breakdown, and ROA Trends | Biogen, Horizon Therapeutics, Bristol-Myers Squibb, AstraZeneca, Sanofi, Amgen
Albany New York November 03 2026 As per DelveInsight s assessment globally Cutaneous Lupus Erythematosus pipeline constitutes 8 key companies continuously working towards developing 10 Cutaneous Lupus Erythematosus treatment therapies…
HUTCHMED and AstraZeneca Seek FDA Approval for Savolitinib Plus Osimertinib in MET-Driven EGFR-Mutated Lung Cancer
The population is large. Lung cancer accounts for almost one in four cancer deaths worldwide, and 80-85% of patients have NSCLC. About 75% of NSCLC patients are diagnosed with advanced disease. EGFR mutations are found in roughly 10-15% of…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- marketscreener.com94
- tradingview.com13
- seekingalpha.com10
- statnews.com8
- defenseworld.net7
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 120 articles, not a forecast.